ZLAB supply chain intelligence for Zai Lab Limited: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Zai Lab Limited (ZLAB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| HALO | Halozyme Therapeutics, Inc. | 72% | Reciprocal relationship from HALO graph: ds. We target large, attractive markets, where ENHANZE-enabled SC delivery has the potential to deliver competitive differentiation and other important benefi… |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: es and clinical testing, and regulatory approval prior to commercial use. The future success of the Company is dependent on its ability to identify and develo… |
| PFE | Pfizer Inc. | 72% | Reciprocal relationship from PFE graph: Item 1A. Risk Factors—Research and Development section. COLLABORATION AND CO-PROMOTION AGREEMENTS We use collaboration and/or co-promotion arrangements to enha… |
| VRTX | Vertex Pharmaceuticals Incorporated | 72% | Reciprocal relationship from VRTX graph: Reciprocal relationship from ZLAB graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from ZLAB graph: Reciprocal relationship from VRTX g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| FIVE-LARGEST-CUSTOMERS | FIVE-LARGEST-CUSTOMERS | 92% | Our five largest customers accounted for approximately 32.4% and 35.0% of our total product revenue in 2024 and 2023, respectively |
| LARGEST-CUSTOMER | LARGEST-CUSTOMER | 92% | As of March 31, 2026, our largest customer accounted for approximately 25% of our total accounts receivable collectively. |
| HALO | Halozyme Therapeutics, Inc. | 72% | Reciprocal relationship from HALO graph: ds. We target large, attractive markets, where ENHANZE-enabled SC delivery has the potential to deliver competitive differentiation and other important benefi… |
| F-11-ZAI-LAB-LIMITED | F-11-ZAI-LAB-LIMITED | 62% | ated statements of operations. F-11 Zai Lab Limited Notes to the Consolidated Financial Statements For the Years Ended December 31, 2024, 2023, and 2022 (e) Cash, Cash Equivalents, and Restricted Cas… |
| F-12-ZAI-LAB-LIMITED | F-12-ZAI-LAB-LIMITED | 62% | from product sales and represent amounts due from its customers. From January 1, 2020, the Company adopted the ASU 2016-13, Credit Losses, Measurement of Credit Losses on Financial Instruments. Accou… |
| F-13-ZAI-LAB-LIMITED | F-13-ZAI-LAB-LIMITED | 62% | from product sales and represent amounts due from its customers. From January 1, 2020, the Company adopted the ASU 2016-13, Credit Losses, Measurement of Credit Losses on Financial Instruments. Accou… |
| F-16-ZAI-LAB-LIMITED | F-16-ZAI-LAB-LIMITED | 62% | the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within th… |
| F-18-ZAI-LAB-LIMITED | F-18-ZAI-LAB-LIMITED | 62% | product revenue, respectively for the same periods. Concentration of Credit Risk Financial instruments that are potentially subject to significant concentration of credit risk consist of cash and cas… |
| HUMAN-GENETIC-RESOURCES | HUMAN-GENETIC-RESOURCES | 62% | “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or similar expressions. Such statements constitute forward-looking s… |
| HUMAN-RESOURCES | HUMAN-RESOURCES | 62% | linical studies, clinical trials, production and distribution, post-market studies, and the monitoring, reporting, and handling of adverse reactions in connection with pharmaceuticals. The marketing … |
| NOVO-HOLDINGS | NOVO-HOLDINGS | 62% | ucture to support the sales of our commercial products. Our sales and marketing teams cover major medical centers across Greater China, and our commercial team has capabilities that cover the product… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ZLAB-DEBT-13765 | Warrants outstanding: 1000000 | 90% | xbrl warrant detail from xbrl 2017-12-31. |
| ZLAB-DEBT | Debt stack $238.1M | 90% | Market cache reports total debt of $238.1M. |
| ZLAB-DEBT-13766 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2017-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| HALO | Halozyme Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| PFE | Pfizer Inc. | 100.00 | 1 | ['supplier'] |
| VRTX | Vertex Pharmaceuticals Incorporated | 100.00 | 1 | ['supplier'] |
| MGNX | MacroGenics, Inc. | 100.00 | 1 | ['supplier'] |
| AMPH | Amphastar Pharmaceuticals, Inc. | 100.00 | 2 | |
| ORKA | Oruka Therapeutics, Inc. | 100.00 | 2 | |
| MCK | McKesson Corporation | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 50.00 | 2 | |
| CELG-RI | BRISTOL MYERS SQUIBB CO | 50.00 | 2 | |
| CLYM | Climb Bio, Inc. | 50.00 | 2 | |
| ORANY | ORANGE | 50.00 | 2 | |
| CAH | Cardinal Health, Inc. | 50.00 | 2 | |
| CRSP | CRISPR Therapeutics AG | 50.00 | 2 | |
| ARVN | Arvinas, Inc. | 50.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 50.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 50.00 | 2 | |
| AZN | AstraZeneca PLC | 50.00 | 2 | |
| COLL | Collegium Pharmaceutical, Inc. | 50.00 | 2 | |
| BMY | Bristol-Myers Squibb Company | 50.00 | 2 | |
| RLAY | Relay Therapeutics, Inc. | 50.00 | 2 |